Limberg, Jacqueline K.

This study aimed to investigate the impact of central α2-adrenergic mechanisms on arterial baroreflex control of sympathetic and cardiovagal outflow in healthy humans. R-R interval (ECG), blood pressure (brachial arterial catheter), and muscle sympathetic nerve activity (MSNA; peroneal microneurography) were measured in eight healthy participants (5 females; 28±7 years). Sympathetic action potentials (AP) were extracted from the filtered MSNA neurogram (continuous wavelet transform) during a 5-minute baseline (BSL) and an intravenous dexmedetomidine infusion consisting of a loading dose (LD; 10 minutes at 0.225 μg/kg/hr) and a maintenance dose (MD; ~0.15 μg/kg/hr). Sympathetic AP baroreflex threshold gain was measured as the slope of the linear relationship between AP discharge probability and diastolic blood pressure. The linear relationship between R-R interval and systolic blood pressure (sequence technique) quantified cardiovagal baroreflex gain. Mixed-effects analyses and post-hoc t-tests were performed. Data are reported as mean ± SD. Dexmedetomidine reset the baroreflex threshold operating points for all sympathetic AP clusters downwards to lower firing probabilities (cluster 4; BSL: 20±6, LD: 13±8, MD: 6±5%, both p<0.01 vs. BSL) and leftwards to lower diastolic pressures (BSL: 72±9, LD: 69±8, MD: 65±10 mmHg, both p<0.01 vs. BSL). Dexmedetomidine reduced baroreflex threshold gain for the subpopulation of medium-sized sympathetic APs (cluster 4; BSL: -6.5±2.0, LD: -2.6±1.6, MD: -2.0±0.7 %/mmHg, both p<0.01 vs. BSL). Dexmedetomidine did not affect baroreflex threshold gain of small (cluster 1; BSL: -1.9±1.1, LD: -1.3±1.6, MD: -1.1±0.8 %/mmHg, both P>0.88 vs. BSL) or large AP clusters (cluster 9; BSL: -0.8±0.4, LD: -0.8±1.0, MD: -0.2±0.7 %/mmHg, both P>0.98 vs. BSL). Dexmedetomidine reset the cardiovagal baroreflex to lower systolic pressures but did not affect R-R interval (BSL: 1035±261, LD: 1025±308, MD: 1005±292ms, Main effect P=0.45) or gain (BSL: 24±11, LD: 30±20, MD: 26±25 ms/mmHg, Main effect P=0.63). These findings suggest that central α2-adrenergic mechanisms differentially affect arterial baroreflex control of sympathetic and cardiovagal outflow in humans by minimally affecting cardiovagal baroreflex gain but strongly affecting the baroreflex gain for the subpopulation of medium-sized sympathetic APs. This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the National Institutes of Health (NIH). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

This study investigated the impact of integrated muscle sympathetic nerve activity (MSNA) discharge patterns on human neurocirculatory regulation. In 13 healthy females (42 ± 15 years), the transduction of integrated MSNA (peroneal microneurography) into mean arterial pressure (MAP; arterial catheter) was studied during an intravenous infusion of a nicotinic ganglionic antagonist (trimethaphan camsylate, 1-7 mg/min). Neurovascular transduction (signal averaging) was studied based on the overall response, burst sequence (singlet, doublet, and triplet+), and burst amplitude (binned into tertials: small, medium, and large bursts). Data (mean ± SD) are reported for a 10-minute baseline (BSL), the one-minute period at the midpoint of the trimethaphan infusion with integrated MSNA bursts (TM-Mid), and the last minute of trimethaphan infusion with integrated MSNA bursts (TM-Last). During BSL, the MAP transduction responses were greatest for triplets+ (singlets: 0.9 ± 0.2 mmHg, doublets: 2.0 ± 0.6 mmHg, triplet+: 2.6 ± 0.9 mmHg; P < 0.01) and large bursts (small: 1.0 ± 0.3 mmHg, medium: 1.7 ± 0.5 mmHg, large: 2.2 ± 0.7 mmHg; P < 0.01). Trimethaphan infusion reduced integrated MSNA burst frequency resulting in a greater proportion of singlets (BSL: 45 ± 18 %, TM-Mid: 75 ± 23 %, TM-Last: 94 ± 20 %; P < 0.01), a lower proportion of doublets, and a lower proportion of triplets+ (BSL: 23 ± 19 %, TM-Mid: 9 ± 18 %, TM-Last: 0 ± 0 %; P < 0.01). Trimethaphan infusion reduced integrated MSNA burst amplitude resulting in a greater proportion of small bursts (BSL: 33 ± 0.2 %, TM-Mid: 60 ± 26 %, TM-Last: 78 ± 37 %; P < 0.01), a lower proportion of medium bursts, and a lower proportion of large bursts (BSL: 34 ± 1 %, TM-Mid: 17 ± 26 %, TM-Last: 1 ± 5 %; P < 0.01). Trimethaphan-mediated changes in MSNA burst frequency and amplitude were associated with reduced overall MAP transduction responses (BSL: 1.6 ± 0.5 mmHg, TM-Mid: 0.5 ± 0.2 mmHg, TM-Last: 0.3 ± 0.3 mmHg; P < 0.01). Linear regression analyses demonstrated that the trimethaphan-mediated reduction in the proportion of large bursts ( β = 0.02 ± 0.008 mmHg/%, R2 = 0.13, P = 0.03) more strongly affected sympathetic neurovascular transduction responses than reductions in the proportion of triplet+ burst sequences (P = 0.91). These findings suggest that time varying MSNA discharge patterns, particularly variations in burst amplitude, support human neurocirculatory regulation. This work was supported by the National Institutes of Health and the Natural Sciences and Engineering Research Council of Canada. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Objectives: Upregulation of endothelin-1 (ET-1) and its receptors have been linked to increases in hypoxic sensitivity of the carotid chemoreceptors and the development of hypertension. As such, chemoreflex sensitization has been shown in pre-clinical models to be attenuated by ET-1 receptor blockade. Herein, we sought to assess a role for ET-1 in the maintenance of resting blood pressure (BP) in healthy young men and determine whether chemoreflex control of BP could be altered by ET-1 blockade. We hypothesized endothelin receptor antagonism with oral bosentan would lower resting BP in healthy young men as well as the acute BP response to hypoxia. Methods: Twenty-four healthy young men (31±5 yrs, 26±3 kg/m2) completed two study visits (control, bosentan) separated by a minimum of 1 week. The nonspecific endothelin receptor antagonist bosentan (62.5 mg) was taken by mouth twice daily for 3 days prior to the second study visit. On each visit, beat-by-beat BP was assessed under 3 inspiratory air conditions: 1) steady-state normoxia (FiO2 0.21), 2) chemoreflex excitation produced by acute, graded hypoxia (FiO2 0.05 – 0.21), 3) chemoreflex inhibition elicited by transient hyperoxia (FiO2 1.00). Results: Oral bosentan treatment resulted in an increase in plasma ET-1 (0.9±0.9 to 1.3±0.6 pg/mL, p=0.004), supporting receptor blockade. Resting diastolic and mean BP were reduced following 3 days of bosentan treatment compared to control (diastolic: 73±5 to 69±7 mmHg, p=0.007; mean: 93±7 to 88±7 mmHg, p=0.005) with no change in systolic BP (p=0.507). Notably, the BP response to both acute hypoxia (-0.48±0.38 to -0.25±0.31 mmHg/%, p=0.004) and hyperoxia (main effect of bosentan, p=0.025) were attenuated following bosentan. Conclusions: Acute oral bosentan treatment resulted in a reduction in resting BP in healthy young men. The effect of endothelin receptor inhibition with bosentan further attenuated the rise in BP during chemoreflex excitation via acute, graded hypoxia as well as the fall in BP during chemoreflex inhibition (transient hyperoxia). Together these data support a role for ET-1 in control of resting BP in healthy young men, possibly through a chemoreceptor-mediated mechanism. NIH HL130339 (JL), Mayo Clinic Center for Biomedical Discovery (JL, SB). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Objective Insulin has known sympathoexcitatory effects that have been historically attributed to primarily central mechanisms. Although controversy exists, recent evidence from rodents suggests the carotid chemoreceptors may play a role in the sympathoexcitatory response to hyperinsulinemia. Therefore, we sought to examine the contribution of the carotid chemoreceptors to insulin‐mediated increases in sympathetic nervous system activity in humans. We hypothesized reductions in carotid chemoreceptor activity would attenuate the sympathoexcitatory response to hyperinsulinemia in humans – thus supporting a role for the carotid chemoreceptors in insulin‐mediated sympathoexcitation. Methods Young, healthy adults (n=15, 8M/7F, 27±1 yrs, 24±1 kg/m 2 ) completed a 30‐min euglycemic baseline followed by a 90‐min hyperinsulinemic (1 mU/kg FFM/min), euglycemic (90–100 mg/dL) clamp. Heart rate (electrocardiography) and muscle sympathetic nerve activity (MSNA, microneurography of the peroneal nerve) were continuously measured. The role of the carotid chemoreceptors was assessed using the following protocols: 1) acute (1‐min) hyperoxia (n=13), 2) low‐dose dopamine (1–4 μg/kg/min; n=7), 3) acute hyperoxia + low‐dose dopamine (n=8). The nadir 15‐s value for MSNA within each hyperoxic condition was determined and the nadir at baseline was compared to the nadir during hyperinsulinemia. Results MSNA increased from baseline during the hyperinsulinemic, euglycemic clamp [12±2 to 18±2 bursts/min (p<0.01)]. In protocol 1, MSNA was reduced during acute hyperoxia at baseline (12±1 to 6±1 bursts/min, p<0.01) and during the hyperinsulinemic clamp (17±2 to 12±2 bursts/min, p=0.02); however, the fall in MSNA during hyperoxia did not differ between baseline and hyperinsulinemia (p=0.82). In protocol 2, when low‐dose dopamine was given prior to the hyperinsulinemic clamp, MSNA did not increase from baseline (19±2 to 22±5 bursts/min, p=0.51); this is in contrast to increases observed under saline conditions (14±3 to 22±4 bursts/min, p=0.03). In protocol 3, in the presence of low‐dose dopamine, MSNA was reduced during acute hyperoxia at baseline (16±3 to 9±2 bursts/min, p=0.048) and during the hyperinsulinemic clamp (16±4 to 9±3 bursts/min, p=0.02); however, the fall in MSNA with hyperoxia did not differ between baseline and hyperinsulinemia (p=0.97). Conclusions Low‐dose dopamine given prior to the onset of a hyperinsulinemic, euglycemic clamp attenuates the sympathoexcitatory response to hyperinsulinemia. In contrast, acute carotid chemoreceptor desensitization (1‐min hyperoxia) during steady‐state hyperinsulinemia does not augment the fall in MSNA observed at baseline. Our data suggest the carotid chemoreceptors do not contribute acutely to insulin‐mediated increases in sympathetic nervous system activity in healthy humans; however, they may play a role during longer‐term exposure. Support or Funding Information Support: DK090541 (MJJ); HL83947 (MJJ); HL130339 (JKL); AHA15SDG25080095 (JKL)

Peripheral chemoreceptors located within the carotid bodies activate cardiorespiratory reflexes in response to hypoxia. Carotid body chemoreceptor activity has been shown to be enhanced in conditions such as congestive heart failure, hypertension, and possibly aging. Nitric oxide (NO) has been proposed as an inhibitory modulator of carotid body chemosensitivity in response to hypoxia. Additionally, NO bioavailability is often reduced with cardiovascular risk factors such as aging. In the present study, we tested the hypothesis that increasing NO bioavailability via dietary nitrate (NO 3 ) supplementation would reduce cardiorespiratory responses to hypoxia in older adults. A double‐blind, randomized, placebo‐controlled, cross‐over study design was used to evaluate minute ventilation (V E ) and heart rate (HR) responses to acute hypoxia in 7 older adults (66±2 years; 5M/2F) before and after 4 weeks of NO 3 supplementation (beetroot powder) and placebo (beetroot powder devoid of NO 3 ). On each study visit, subjects underwent two separate isocapnic hypoxic tests (self‐regulating, partial rebreathing system with 10% O 2 ). Subjects remained on 10% O 2 until SpO 2 reached ≤80%. The hypoxic exposures were separated by a 15‐minute washout period with the subjects breathing room air. V E , HR, and SpO 2 were continuously monitored throughout each hypoxic exposure. Data were grouped together using a 7‐breath average with the slope of the linear regression line for each dependent variable (V E and HR) versus SpO 2 serving as a measure of peripheral chemosensitivity. The slopes for the two hypoxia tests on each study visit were averaged and used for statistical comparisons. On study day one (true baseline) acute hypoxia increased both V E and HR ( P <0.05 for both). Four weeks of NO 3 supplementation reduced the hypoxic ventilatory response (−0.16 ± −0.05 vs. −0.06 ± −0.03 L/minute/%SpO 2 , P <0.05), whereas no change was observed following the placebo phase of the study (−0.14 ± −0.07 vs. −0.14 ± −0.08 L/minute/%SpO 2 , P=0.67). Additionally, the heart rate responses to acute hypoxia were also reduced following NO 3 supplementation (−0.49 ± −0.08 vs. −0.30 ± −0.05 beats/minute/%SpO 2 , P <0.05), but not with placebo (−0.54 ± −0.11 vs. −0.45 ± −0.08 beats/minute/%SpO 2 , P=0.21). Our preliminary findings suggest that supplementation of NO 3 to boost NO bioavailability in older adults blunts the cardiorespiratory responses to hypoxia. Future studies should examine the therapeutic potential of NO 3 in patient populations exhibiting exaggerated peripheral chemosensitivity. Support or Funding Information Research supported by Neogenis Inc.

Post‐mortem analyses have identified carotid body hypertrophy in conditions of chronic hypoxemia, including sleep apnea; however, post‐mortem assessment limits the clinical relevance of such findings. We tested the hypotheses that: 1) carotid body size can be detected in living individuals by computed tomographic angiography (CTA), and 2) patients with sleep disordered breathing [Apnea Hypopnea Index (AHI) ≥ 30 events/hour] exhibit larger carotid bodies than those without sleep disordered breathing (AHI < 5 events/hour). A chart review was conducted from patients seen at the Mayo Clinic between January 2000 and February 2015 who had undergone neck CTA and polysomnography. From an initial pool of 583, 109 patients met our strict inclusion criteria. Widest axial measurements of the right and left carotid bodies were performed independently by two radiologists blinded to condition and average carotid body size was calculated for each patient of interest. Carotid body identification was possible in 81% of patients. Intra‐class correlation coefficients ranged from 0.93 to 0.95 (right carotid body: 0.93; left: 0.94; average: 0.95). From subjects with identifiable carotid bodies, widest axial measurements were greater in patients with high AHI (n=32; right: 2.9±0.2mm, left: 3.1±0.2mm, average: 3.0±0.1mm) compared to patients with low AHI (n=46; right: 2.5±0.1mm, left: 2.7±0.1mm, average: 2.6±0.1mm; p=0.04, p=0.04, p=0.02, respectively). Because participants in the high AHI group were significantly older than those in the low AHI group (65±2 years vs. 50±2 years; p<0.01), an analysis of covariance was performed to control for the influence of age on carotid body size. After adjusting for age, no differences in carotid body size were observed between the patient groups (p=0.45, p=0.59, p=0.54 for right, left, and average carotid body, respectively). Main findings are two‐fold: 1) carotid body size can be identified by CTA in approximately 80% of patients with good inter‐observer agreement, and 2) adults that exhibit sleep disordered breathing do not have larger carotid bodies when compared to controls, after adjusting for age. Support or Funding Information This work was supported by the National Institutes of Health [grant numbers T32 GM008685 (ARE), R01 DK090541 (MJJ)].

Background Nitric oxide (NO) contributes ~30% to the rate of vasodilation during dynamic exercise in healthy humans. This NO‐mediated dilation occurs via increases in cyclic guanosine monophosphate (cGMP), which is catabolized by phosphodiesterase‐5 (PDE‐5). Therefore, we sought to determine the nature of NO‐cGMP signalling to the exercise vasodilator response in healthy humans. We hypothesized the time‐course of exercise vasodilation would be: 1) accelerated by sildenafil citrate (SDF, PDE‐5 inhibitor) 2) slowed by the NO synthase inhibitor L‐N G ‐monomethyl arginine (L‐NMMA) 3) similarly slowed by the combination of SDF+L‐NMMA. Methods Data from 29 healthy individuals were included in the present study. All subjects completed 5‐min of dynamic forearm exercise at 15% of maximal voluntary contraction under control conditions (CON, arterial saline infusion), followed by an identical exercise protocol during: 1) PDE‐5 inhibition via SDF (100mg oral dose, n = 8), 2) NOS inhibition via intra‐arterial infusion of L‐NMMA (50 mg loading dose and 1 mg/min maintenance dose, n = 15), or 3) combined SDF+L‐NMMA (n = 6). Forearm blood flow (FBF; Doppler ultrasound) and mean brachial artery blood pressure (MAP, transducer) were measured continuously. To determine time to steady‐state vasodilation, forearm vascular conductance (FVC = FBF/100mmHg/dL FAV) data were curve fit with a monoexponential model and mean response time (MRT, time to achieve 63% of steady state response) was calculated. In addition, the increase in relative forearm vascular conductance from rest to steady state exercise (average of the last 30s of exercise, ΔFVC = FVC exercise − FVC rest ) was used to assess the total vasodilatory response. Results Data are reported as mean ± SE (FVC = mL/dL/100mmHg/min, MRT = s) . In contrast to our hypothesis, SDF alone had no effect on exercise vasodilation (Δ FVC CON = 20±3 vs. SDF = 21±3, p = 0.50) or time to steady‐state vasodilation (MRT: CON = 32± 7 vs SDF= 33±4, p = 0.90) in young healthy adults. NOS inhibition with L‐NMMA reduced ΔFVC (CON = 16±2 vs. L‐NNMA = 14±1, p = 0.049) and increased the time to reach steady‐state vasodilation (MRT: CON = 22±5 vs. L‐NMMA = 40±6, p = 0.01). Surprisingly, when subjects were given L‐NMMA combined with SDF, reductions in Δ FVC or increases in MRT were no longer observed (Δ FVC: CON = 23±4 vs. SDF+L‐NMMA = 23±6, p = 0.90; MRT: CON = 45±8 vs. SDF+L‐NMMA = 49±11, p = 0.80). Conclusion These data indicate inhibiting PDE‐5 during moderate exercise does not improve the magnitude or time‐course of vasodilation. Whereas, NOS inhibition limits the magnitude and time‐course of the vasodilatory response to dynamic handgrip exercise in healthy adults, combined inhibition of PDE‐5 restores the response to control levels. These data suggest PDE‐5 inhibition does not potentiate the NO‐cGMP pathway during moderate exercise. However, PDE‐5 inhibition may have therapeutic use in pathologies where limited NO bioavailability may contribute to impaired blood flow responses to exercise. Support or Funding Information American Heart Association (15POST23100020) ‐ JMKNational Institutes of Health (HL46493) ‐ MJJ National Institutes of Health (HL078019) ‐ MJJ National Institutes of Health (HL105820) ‐ WGS National Institutes of Health (RR17520) ‐ N/A National Institutes of Health (UL1 TR000135) ‐ N/A

Background The risk of hypertension increases as women reach menopause. Our group has recently reported that autonomic support of blood pressure (BP) is increased in post‐menopausal women. Given regular exercise is known to decrease the risk of developing hypertension, we investigated the role of aerobic fitness on autonomic support of BP in women. We hypothesized that trained premenopausal, but not postmenopausal, women would have less autonomic support of BP than age‐matched untrained women. Methods Twelve healthy, young premenopausal (27±1yrs) and 10 older postmenopausal (56±1yrs) women completed VO 2max tests on cycle ergometers. The participants were then stratified by fitness level based on VO 2max percentiles from the American College of Sports Medicine's Guidelines (≤50 th percentile = untrained; >50 th percentile = trained; premenopausal: 7 untrained, 5 trained; postmenopausal: 5 untrained, 5 trained). On a separate day muscle sympathetic nerve activity (MSNA, microneurography, peroneal nerve), heart rate (electrocardiography), and blood pressure (brachial arterial catheter) were recorded before and during ganglionic blockade using trimethaphan camsylate (dose:1.5–7mg/min). Stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) were calculated from the blood pressure waveform (WinCPRS). Results Muscle sympathetic nerve activity was higher in trained young women than in untrained young women (burst incidence: 35±11 vs. 12±2 bursts/100 heart beats, p=0.03). Young trained women had a smaller reduction in mean arterial pressure (MAP) with trimethaphan than young untrained women (ΔMAP:−5±3 vs. −15±4mmHg, p=0.01), despite a larger reduction in total peripheral resistance (ΔTPR: −6±1 vs. −2±1mmHg*min/L, p=0.02). The trained young women were able to maintain their MAP due to a greater increase in cardiac output (ΔCO: 1.4±0.4 vs. −0.3±0.3L/min, p= 0.01). In older postmenopausal women, MSNA and the fall in BP, CO, and TPR with trimethaphan were not different between trained and untrained individuals (p= 0.81, 0.16, 0.52 and 0.09, respectively). Conclusion Baseline MSNA was higher in trained premenopausal women when compared to untrained premenopausal women; however, aerobic fitness did not influence baseline MSNA in postmenopausal women. In young trained women, the fall in MAP following ganglionic blockade was only one‐third of the response seen in young untrained women. Baseline MSNA and the change in MAP, CO, and TPR with ganglionic blockade were not different between trained and untrained postmenopausal women. These data suggest aerobic fitness reduces autonomic support of blood pressure in young trained women, but not in trained postmenopausal women. Support or Funding Information Support: HL83947 (MJJ); HL131151 (SEB), DK 7352‐37 (SEB), HL118154 (JNB)

Purpose Obese adults exhibit increased levels of inflammation which may negatively affect blood pressure regulation. Based on existing literature, we hypothesized: 1) baroreflex sensitivity would be lower in obese adults when compared to lean adults and 2) acute ibuprofen (IBU, a cyclooxygenase inhibitor and nonsteroidal anti‐inflammatory agent) administration would increase baroreflex sensitivity in obese adults, with no effect in lean adults. Methods Seven lean (4M, 3F; 25±2 yrs; 23±1 kg/m 2 ) and six obese (5M, 1F; 30±3 yrs; 36±1 kg/m 2 ) adults completed two visits randomized to control (CON) or IBU (800 mg oral). On each visit, blood pressure (intra‐arterial catheter), heart rate (electrocardiogram), and muscle sympathetic nerve activity (MSNA, microneurography) were measured continuously and venous blood was sampled for measures of systemic inflammation [C‐Reactive protein (CRP) and Interleukin‐6 (IL‐6)]. Sympathetic and cardiac baroreflex sensitivity were assessed using the modified Oxford technique, which consisted of a 5‐min resting period, followed by a 100 μg intravenous bolus of sodium nitroprusside. One minute later, subjects were administered a 150 μg intravenous bolus of phenylephrine HCl and data were collected for an additional 2‐min. Results CRP and IL‐6 were higher in obese adults when compared to lean adults, and tended to decrease with IBU (IL‐6: p<0.05; CRP: p=0.14). Cardiac baroreflex sensitivity was lower in obese adults (14±2 vs 24±2 ms/mmHg, p=0.02), whereas sympathetic baroreflex sensitivity was higher in obese adults (−3.6±0.5 vs −2.1±0.5 bursts/100 beats/mmHg, p=0.03) when compared to lean. There was no effect of IBU on cardiac or sympathetic baroreflex sensitivity in either group (p‐value range 0.20 – 0.71). Conclusion In our present group of relatively healthy individuals with obesity, we observed lower cardiovagal baroreflex sensitivity but higher sympathetic baroreflex sensitivity in the obese group compared to lean controls. We found no effect of an acute dose of 800 mg ibuprofen on cardiac or sympathetic baroreflex sensitivity, suggesting that chronic effects of obesity‐related inflammation on baroreflex sensitivity may not be reversed by a single acute pharmacological anti‐inflammatory intervention. Support or Funding Information NIH HL083947 (NC, MJJ), DK082424 (TBC), AG038067 (JNB), and UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS). AHA 0750036Z (NC) from the American Heart Association.

Background Patients with sleep apnea experience repeated, intermittent hypoxic exposures during sleep and are at increased risk of developing hypertension. The mechanisms that contribute to high blood pressure in these patients are not completely understood. In this context, we sought to examine the effect of intermittent hypoxic exposures on baroreflex sensitivity and blood pressure. We hypothesized 3‐hours of intermittent hypoxia would result in a decrease in baroreflex sensitivity in healthy adults. We further hypothesized any decrease baroreflex sensitivity would be related to an increase in blood pressure following intermittent hypoxia. Methods Six (5M/1F) young healthy, non‐obese, subjects without sleep apnea completed 3‐hours of intermittent hypoxia. Intermittent hypoxia consisted of 25‐second exposures to hypoxic gas (0.05 F i O 2 ) separated by 2 minutes of room air breathing, resulting in 25‐hypoxic events per hour in which oxygen saturation (S p O 2 ) was significantly reduced (Normoxia: 97%, Hypoxia: 89%, p<0.01). Beat‐to‐beat heart rate (electrocardiogram) and blood pressure (finger photoplethysmography) were measured continuously. Spontaneous cardiac baroreflex sensitivity was determined using the sequence method (WinCPRS) and data are reported from 10‐minutes of quiet, normoxic rest before and after the intermittent hypoxia protocol. Results We observed a significant reduction in spontaneous cardiac baroreflex sensitivity to falling pressures (“down‐down”) following intermittent hypoxia (Control=22±2, IH=15±2 ms/mmHg; p=0.02). No change in baroreflex sensitivity to rising pressures (“up‐up”) was observed (Control=25±2, IH=20±6 ms/mmHg; p=0.41). A relationship between baroreflex sensitivity and mean arterial blood pressure was observed, such that a reduction in baroreflex sensitivity tended to be related to an increase in blood pressure (“down‐down”: R=−0.45, p=0.14; “up‐up”: R=−0.54, p=0.07). Conclusions Intermittent hypoxia results in a decrease in baroreflex sensitivity, which is related to an increase in blood pressure. These data may have important implications for mechanisms contributing to the risk of hypertension in individuals with sleep apnea. Support or Funding Information DK90541 (MJJ), HL120570 (JKL)